Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability

10.1111/j.1528-1167.2012.03696.x

10.1002/jps.10256

10.1146/annurev.pharmtox.39.1.361

10.1186/1471-2377-9-S1-S3

10.1080/10611860701794395

10.1016/j.apsb.2013.12.012

10.1211/jpp.62.07.0013

Chen YM, 2004, Chin J Integr Tradit Western Med, 24, 632

Chen ZZ, 2014, Zhong Yao Cai, 37, 460

10.1371/journal.pone.0101414

10.1016/j.ijpharm.2013.08.017

10.1038/aps.2013.86

10.3390/molecules170910258

10.1016/S0301-0082(96)00033-0

10.1111/j.1600-0714.2008.00738.x

10.2174/156802609787521571

Dong XP, 2012, Chin Tradi Herb Drugs, 43, 1366

10.3390/ijms161126051

10.2174/138920112800624409

10.1211/jpp.62.03.0011

10.1016/j.bcp.2005.01.002

10.1016/j.fct.2009.03.002

10.1038/aps.2009.148

Huang P, 2009, Tradit Chin Med Mater Med, 11, 821

Jiang XF, 2008, Mode Tradit Chin Med Mater Med, 10, 27

10.1007/s11033-010-0184-1

10.1046/j.1365-2249.1998.00648.x

10.1007/s13318-011-0058-5

Li WR, 2004, J Chin Med Mater, 27, 937

Li WR, 2006, J Clin Rehab Tissue Eng Res, 10, 167

Liang MR, 1993, Tradit Chin Drug Res Clin Pharmacol, 4, 38

Liu YD, 2008, Chin J Chin Mater Med, 33, 259

10.1602/neurorx.2.1.86

10.3390/ijms131114127

10.1161/01.STR.26.5.857

10.1016/j.brainres.2011.04.003

Ni CX, 2011, Chin J Chin Mater Med, 36, 2562

10.1602/neurorx.2.1.3

10.1016/j.bbamem.2007.08.004

10.1016/S0006-2952(02)01444-2

10.1023/A:1025092829696

10.1016/j.ejpb.2012.10.018

10.1038/nrm1593

10.1111/j.1469-7793.1998.909bs.x

10.3389/fnins.2015.00385

10.1002/jnr.23457

Shi L, 2014, Int J Nanomed, 9, 4437

10.1016/j.mrgentox.2009.05.016

Song X, 2012, Pharmazie, 67, 848

State Pharmacopoeia Committee, 2015, The Pharmacopoeia of People's Republic of China

10.1039/C5RA22233H

Wang LP, 2014, Zhongguo Zhong Yao Za Zhi, 39, 949

Wang NS, 1992, Tradit Chin Drug Res Clin Pharmacol, 3, 28

10.4314/tjpr.v13i1.6

10.1007/s13318-013-0135-z

Wu SR, 2004, Chin Pharm J, 39, 289

Xian JW, Chan CW, Leung WN, et al. (2013). Borneol enhanced permeability of levodopa across blood-brain barrier _ Potential to lower levodopa dosage for Parkinson’s disease treatment. The 11th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PDTM 2013), 2013, 288 p.

10.1016/j.ijpharm.2006.12.034

10.1093/chromsci/46.5.395

10.1080/10286020.2014.916282

Xiong ZY, 2013, Zhongguo Zhong Yao Za Zhi, 38, 786

10.1016/j.ejps.2016.02.015

10.1177/147323000903700322

Yu B, 2011, Zhen Ci Yan Jiu, 36, 335

Yu B, 2011, Neural Regen Res, 6, 1876

10.1016/j.jpba.2013.01.017

Yu B, 2012, Chin Pharmacol Bull, 28, 862

10.1016/j.jep.2013.10.028

10.1155/2016/4072809

Zeng CQ, 2004, J Chin Med Mater, 27, 347

Zhai ZH, 2010, Chin Med J Res Prac, 24, 86

10.5246/jcps.2011.06.075

10.1007/s11095-013-1055-y

Zhang N, 2012, Neural Regen Res, 7, 440

10.1016/j.jep.2015.01.003

Zhao BS, 2002, Tradit Chin Drug Res Clin Pharmacol, 13, 287

10.1631/jzus.B1200142